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INTRODUCTION
Non-Hodgkin's lymphomas (NHL) are one of only a small number of human cancers that have been increasing in incidence over the last three decades 1, 2 . NHL are a heterogeneous group of lymphoid tumors, >80% of which are derived from the B lymphoid lineage (NHL-B). Most NHL-B are derived from the B2 subset of mature B cells, usually associated with germinal centers (GC) 3, 4 . Two important forms of NHL-B, small lymphocytic lymphoma/chronic lymphocytic lymphoma (SLL/CLL) and Mantle cell lymphoma (MCL) usually express CD5
and appear to be derived from the B1 subset [4] [5] [6] . SLL/CLL and MCL, while sharing CD5+, B1
cell lineage characteristics, have quite different cellular, genetic, and clinical characteristics.
SLL/CLL is an indolent lymphoma often associated with low grade B cell leukemia, which is sensitive to chemotherapy, with a relatively good survival 7, 8 . MCL however, is an aggressive lymphoma that is quite refractory to standard chemotherapy with an overall poor prognosis, although newer therapies have recently improved these patients' outlook 9, 10 .
Clinically, MCL presents with a male predominance in the sixth decade of life, with a mean survival of 40 months. A more aggressive form, the blastoid variant MCL (MCL-BV) presents at an earlier age and has a mean survival of less than 20 months. Besides involvement of the bone marrow, lymph nodes and spleen, there is frequently involvement of the colon and lungs. Approximately 25% of patients have a leukemic phase to their disease and 6% of patients develop central nervous system involvement. 9, 11 .
Mantle cell lymphoma is strongly associated with chromosomal abnormalities including the translocation t (11;14) and deletion of 11q22-23 [12] [13] [14] . The involvement of the ATM and cyclin D1 genes in this disease has been postulated from these abnormalities 13 . The deletion of 13q14 commonly seen in B-CLL also occurred in 70% of patients with MCL, suggesting overlapping genetic disorders in these two diseases 15 .
Increased expression of bcl-2 and c-Myc
For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From is seen in most cases of MCL 9, [16] [17] [18] [19] [20] with the anti-apoptotic bcl-2 often increased in expression in many lymphoid malignancies 21 . Myc proteins participate in oncogenesis in a wide variety of tumors by a number of different mechanisms, including increasing the entry of cells into the cell cycle, regulating the transcription of many relevant genes, and inducing genomic instability [22] [23] [24] [25] [26] .
The NF-κB family of transcription factors are central mediators in the growth and survival of MCL [27] [28] [29] [30] , consisting of 5 members, c-rel, RelA (p65), RelB, NF-κB1 (p50/p105) and NF-κB2
(p52/p100) 31 .
Currently, there are no spontaneous animal models for MCL, although xenotransplantation models have been produced in SCID mice growing human MCL cells 32, 33 . In addition, a candidate MCL model has recently been created in Eµ-cyclin D1 transgenic Balb/c mice treated with three monthly intraperitoneal injections of the tumor promoter pristane 34 .
Interleukin 14 was identified in a Burkitt lymphoma cell line and initially called high molecular-weight B cell growth factor (HMW-BCGF) 35 . It acts as a growth factor for germinal center B-lymphocytes, B1 cells and memory B cells 35, 36 . IL-14 is also a potent growth factor for B-CLL in vitro 37 . Two transcripts are derived from the IL-14 gene, which have been designated IL-14α and Il-14β. Transgenic mice expressing IL-14α constructed with the pEµSR vector develop autoimmunity and large B cell lymphomas by 18 months of age 38 . The expression of IL-14α mRNA has been identified in high grade B cell tumors in vivo, and IL-14 antisense oligonucleotides inhibit these tumors in vitro 39 .
We describe here the development of lymphoid malignancies closely resembling the blastoid variant of MCL (MCL-BV) in IL-14α x c-Myc double transgenic mice (DTG), each produced using the vector pEµSR that directs transgene expression in the B cell compartment 40 .
The DTG mice develop an aggressive, monoclonal CD5+, CD19+, IgM+, and cyclin D1+ B cell lymphoma early in life that involves the bone marrow, lymph nodes, spleen, lungs, colon and rarely the central nervous system. Increased expression of bcl-2, ATM, RelA and NF-κB2 is
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From noted along with the translocation of the NF-κB proteins to the lymphoma cell nucleus. This is the first animal model that spontaneously develops lymphoma consistent with human MCL-BV. RT-PCR was performed as described 38 . The primers used for, cyclin D1, bcl-2, ATM, RelA, RelB, NF-kB1, NF-kB2, IL-14α, c-Myc, PAK and Actin were:
METHODS
Cyclin D1 forward primer, 5'-AGAAATCCAATGGGGTTGGA, Cyclin D1 reverse primer, 5'-CTACGTAGCCTTCAACACAT.
Bcl-2 forward primer, 5'-GACTTCGTAGCAGTCATCCT. RT-PCR products were separated on 1% agarose gels and visualized by UV light after incorporation of ethidium bromide, as described 41 .
Morphologic and Immunohistochemical Analysis
Lymphoma tumor tissue and mouse organs were harvested from IL-14α transgenic, cmyc transgenic and DTG transgenic mice, placed in 10% formalin (Baxter Diagnostics) and embedded in paraffin. Thin sections were prepared on slides and the slides stained with the For personal use only. on October 3, 2017. by guest www.bloodjournal.org From HISTOMOUSE-MAX kit (Invitrogen) as instructed by the manufacturer. Anti-mouse CD5 and B220 antibodies were purchased from BD Pharmingen. Anti-Cyclin D1 antibody was purchased from Lab Vision Corp (Fremont CA.)
Flow Cytometry
Cells collected from spleens, lymph nodes or tumor tissue of the mice were stained with panels containing anti-mouse antibody CD19-APC, CD138-PE, CD21-FITC, CD5-PE-Cy5, CD23-PE, IgD-FITC (BD Pharmingen), CD38-PE-Cy5 (eBioscience) and IgM-PE (ABcam) and analyzed on a BD Biosciences FACSCalibur machine and Winlist software.
Immunoglobulin Gene Rearrangements
Ig gene rearrangements for clonal B cell determination of mouse tumor was performed by high fidelity PCR using 0.1 mg of DNA extracted from normal C57BL/6J mouse liver, 
Spectral Karyotyping (SKY)
Spectral karyotyping was performed as previously described 42 . In short, metaphase chromosome spreads were prepared from murine lymphoma cells using standard hypotonic treatment and fixation. They were then denatured with 70% formamide and hybridized with the murine SKY probes (Applied Spectral Imaging, Carlsbad, CA). Chromosomes were isolated by high resolution flow sorting and tagged with different combinations of digoxigenin, Texas red, Cy5, biotin/streptavidin, and Cy5.5. SKY images were captured using the Spectral Curve / Interferometer, and karyotypes were prepared using SKYView software (Applied Spectral Imaging).
Western Blot for Human IL-14α
The Western blot for human IL-14α in lymphoma cells was performed as previously described 39 .
NF-kB Translocation
Translocation of NF-κB to the nucleus was detected using EMSA analysis and Western blot analysis as previously described 29 . Antibodies to NF-κB proteins were purchased from Santa Cruz Biotech (Santa Cruz, CA).
Oversight
The animal studies were all approved by the IACUC, SUNY at Buffalo School of Medicine and Biomedical Sciences. Lymphoma cells were obtained from patients at MD Anderson Cancer according to the local IRB.
RESULTS

Characteristics of the Malignancy in IL-14α TG x c-Myc TG (DTG) Mice
Since IL-14 is expressed in high-grade B cell lymphomas, many of which also express cMyc, we evaluated whether c-Myc could accelerate tumor formation in IL-14α TG mice 39 .
Previous studies had demonstrated that 95% of C57BL/6 IL-14α TG mice develop CD5+, CD19+, sIgM+, cyclin D1negative large B cell lymphomas by 16-18 months of age 38 . We crossed c-Myc transgenic mice, produced with the same vector as the IL-14α transgenic mice 40 ,
with IL-14α TG mice to obtain double-transgenic mice (DTG). DTG mice develop a B cell malignancy within four months in every animal that is characterized by an initial leukemic phase ( Figure 1A ) preceding the appearance of dramatic, wide spread lymphadenopathy and splenomegaly ( Figure 1B) . DTG mice at 2 months of age have high peripheral white blood cell counts that are 1.5 -3 times higher than littermate controls with 10-50% leukemic blasts.
Lymphoma can readily be demonstrated in the bone marrow ( Figure 1C TG mice, c-myc TG mice and DTG mice all expressed CD5 ( Figure 2D ) and CD19 ( Figure 2B and 2D) 38 . The tumors of the IL-14α TG and DTG mice expressed sIgM, but the tumors from the c-myc TG mice did not, as would be expected of a pre-B cell tumor ( Figure 2D ) 40 . We have demonstrated that the mRNA for the NF-κB family members RelA and NF-κB2 are over-expressed and constitutively activated in the tumors from the DTG mice, but not from the IL-14α TG or c-myc TG mice ( Figure 5C ). To demonstrate that NF-κB is constitutively active in the DTG tumors, we also demonstrated nuclear translocation of these proteins by EMSA analysis and Western blotting in the DTG lymphoma cells ( Figure   5D -E) [59] [60] [61] . Because of the translocation involving chromosome 3 and the potential involvement of PAK in regulation of cyclin D1, we evaluated the expression of PAK in the DTG tumors.
Figure 5B demonstrated that PAK is over-expressed in DTG tumors, weakly expressed in IL-14α TG tumors, but is not expressed in c-myc TG tumors.
Transplantation of DTG Lymphoma Cells into Immune Deficient SCID Mice.
Although the DTG lymphoma appears to display all of the requisite characteristics of an aggressive NHL-B, it was important to determine if the DTG lymphoma cells could be successfully transplanted. For these studies, DTG lymphoma cells from one of the recently Immuno-histochemistry of the tumors growing in the SCID mice expressed B220, CD5, and cyclin D1, identical to the original DTG lymphoma ( Figure 6C ).
DISCUSSION
In these studies, we demonstrate the production of a murine lymphoma model that . The rapid onset and the high rate of penetrance (close to 100%) of MCL-BV in the DTG mice suggest that IL-14α is playing a critical role in the development of these tumors.
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The DTG/MCL-BV murine model closely resembles the human counterpart except for the lack of the syntenic equivalent translocation t (11;14) involving the cyclin D1 gene.
Interestingly, MCL has been described in a small number of patients without the t (11;14) translocation. In all of these cases cyclin D1 was not highly expressed and utilization of other D cyclins was implicated in the pathophysiology of the tumors 73, 74 . In the tumors of DTG mice, however, cyclin D1 is overexpressed ( Figures 2C, 2E, 3B, 6C ), so another mechanism(s) for cyclin D1 dysregulation besides t(11;14) must be present. The expression of cyclin D1 is complex, and may require constitutive nuclear expression to induce B cell lymphoma. A number of genes have been implicated in the regulation of cyclin D1 transcription and translation, including PAK , which maybe involved in the 3:10 translocation identified by SKY ( Figure 4 ) and is over-expressed in the DTG tumors ( Figure 5B ) [75] [76] [77] .
Recent studies have suggested that besides cyclin D1, both NF-kB and ATM are critical for MCL 5, 11, 29, 58 . A characteristic deletion 11q22-q23 found in MCL involves ATM 5, 13 . The t(3:10) translocation identified in the DTG tumors may involve ATM as well (Figure 4 ). The levels of ATM expression were not, however, found to be significantly different among normal spleen and tumors from c-Myc TG, IL-14α TG and DTG mice (data not shown). In contrast, significant elevations of RelA and NF-κB2 mRNA were identified in the DTG tumors ( Figure   5C ). NF-κB was constitutively activated and expressed in the nucleus of these tumors, as has been described in many NHL-B lymphomas, suggesting that it was active in the disease process ( Figure 5D and 5E). 
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